Bicara gains buy rating as BofA sees SoC potential in cancer drug Ficera
Corroborated by 2 sources from 2 publishers
globalhealth1d ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, the analysts pointed to the company’s lead asset ficerafusp alfa (ficera) as the central driver of their outlook.